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Abstract
Background: Increasing evidences show that beyond its role in coagulation, endothelial protein C receptor (EPCR)
interferes with carcinogenesis. Pro-carcinogenic effects of EPCR were linked with a raised generation of activated
protein C (aPC) and anti-apoptotic signalling. This study was carried out to analyze the expression, cell surface
exposition, and shedding of EPCR in normal and malignant prostate cell lines.
Results: EPCR expression is up-regulated both at the mRNA and protein levels in invasive prostate DU-145 and PC-
3 cells in comparison to normal prostate epithelial cells (PrEC) and less-invasive LNCaP cells. Release of soluble
EPCR (sEPCR) is induced by 12-myristate 13-acetate, ionomycin, H2O2, and disruptor of lipid rafts in PrEC, DU-145,
and PC-3 cells. Furthermore, interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a), but not interleukin-6 or
interferon-g increase sEPCR release. In LNCaP cells, neither pharmacological agents nor IL-1b or TNF-a result in a
significant increase of sEPCR release. The effects of IL-1b and TNF-a on EPCR shedding in DU-145 cells are
mediated by MEK/ERK 1/2, JNK, and p38 MAPK signalling cascades. In PC-3 cells, however, the MEK/ERK 1/2
pathway is down-regulated and incubation with cytokines did not elevate the phosphorylated ERK-1/2 fraction as
in the case of DU-145 cells. Treatment with 4-aminophenylmercuric acetate (APMA), an activator of
metalloproteases, causes a disproportionately large increase of sEPCR release in DU-145 and PC-3 cells, compared
to PrEC and LNCaP cells. Finally, an increased release of sEPCR mediated by APMA treatment is shown to be
connected with reduced generation of activated protein C indicating the functionality of EPCR in these cells.
Conclusions: The study demonstrates a number of substantial differences in expression and shedding of EPCR in
prostate cancer cell lines in comparison with normal cells that may be relevant for understanding the role of this
receptor in carcinogenesis.
Background
Prostate cancer remains one of the most common forms
of cancer affecting men today [1]. Patients with meta-
static hormone-refractory prostate carcinoma often have
dramatic and life-threatening coagulation complications
from their disease characterized by both induced coagu-
lation and bleeding diathesis [2,3]. Frequently, dissemi-
nated intravascular coagulation is a complication in
prostate cancer patients. Additional coagulopathies in
these patients are thrombocytopenic thrombotic pur-
pura, thrombosis, Trousseau’s syndrome, and acquired
factor VIII inhibitor development [2]. A causal link
between cancer and thrombosis seems related to
abnormally high levels of coagulation factors and
reduced levels of natural anticoagulants [4,5]. In cancer
patients there is a constantly up-regulated generation of
thrombin with potential procarcinogenic actions that
can be counteracted by anticoagulant and anti-inflam-
matory protein C/thrombomodulin-mediated mechan-
isms [6-8]. Such relationships provide a rationale for
studies of the activity and function of the anticoagulant
protein C (PC) pathway in malignancy and metastasis
[8-10]. This PC-pathway includes as key components
the thrombin-thrombomodulin complex and the
endothelial protein C receptor (EPCR) acting as a co-
receptor [11].
Activated protein C (aPC) has divergent effects on
tumour cell migration, invasion, and metastasis. On the
one hand, aPC acts as a pro-carcinogenic agent by way of
EPCR- and PAR-1-mediated survival- and anti-apoptotic
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exert anti-metastatic effects by inhibiting cancer cell
adhesion, extravasation, and cancer cell-induced vascular
leakage [15,16]. Both expression and functional activity
of EPCR in prostate cancer cells are still unknown. In
view of convincing evidence that EPCR, beyond its effects
on coagulation, interferes with carcinogenesis, the pre-
sent study was carried out to analyze the expression, cell
surface exposition, and shedding of this receptor in nor-
mal and malignant prostate cell lines.
Results
Differential expression of endothelial protein C receptor
in prostate cancer cells
In comparison to normal human prostate epithelial cells
(PrEC), levels of EPCR-specific mRNA were higher in
PC-3 and DU-145 cells and lower in LNCaP cells (Fig-
ure 1A). At protein levels, similar results were indicated
by flow cytometry analyses using anti-EPCR monoclonal
antibody (Figure 1B). In DU-145 and PC-3 cell lines,
EPCR-specific immunofluorescence signals were 2.4-
and 5.1-fold higher in comparison to normal cells
(PrEC), whereas the EPCR signals in LNCaP cells were
negligible.
To examine possible relationships between invasive
potential and levels of EPCR in cancer cells, we next
studied the invasion activity of normal and malignant
prostate cells. For this purpose, an Oris™ novel fluores-
cence assay was utilized to monitor movement of cells
through detection zones in a 3-D extracellular matrix.
This analysis indicated distinctly higher invasion of PC-
3 and DU-145 cells into 3D matrix than invasion of
LNCaP cells and PrEC (Figure 2A). A positive relation-
ship (r = 0.89) was observed between levels of cell sur-
face EPCR (flow cytometry data) and numbers of
invading cells within the 3D matrix (Figure 2B).
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Figure 1 Expression of endothelial protein C receptor in normal and malignant prostate cells. (A) Agarose gel electrophoresis with
ethidium bromide-stained amplificates of EPCR and GAPDH-specific mRNA in normal prostate epithelial cells and prostate cancer cell lines. M,
100 bp molecular weight ladder; PrEC, prostate epithelial cells; LN, LNCaP cells; and DU, DU-145 cells. Numbers at the top of the images
represent the ratio of EPCR/GAPDH mRNA calculated from the densitometry values of amplificates. Data are representative of three independent
experiments giving similar results. (B) Flow cytometry analysis of EPCR immunoreactivities in prostate cells. Cells were incubated with anti-EPCR
RCR-252 monoclonal antibodies followed by incubation with FITC-conjugated secondary antibodies and fixation of cells. Black shading represents
tracks obtained with specific primary antibodies; gray shading shows control cells treated with corresponding isotype IgG. Values at the bottom
of images represent the mean fluorescence intensities (MFI) corrected for values in related controls. Results are the means ± SDs of analyses in
duplicates obtained in three similar experiments.
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shedding in prostate cells
In normal PrEC as well as DU-145 and PC-3 cells, the
release of sEPCR was stimulated by pharmacological
inducers such as phorbol-12-myristate 13-acetate (PMA),
ionomycin, H2O2,a n dm e t h y l - b-cyclodextrin (MbCD)
(Figure 3A). The most prominent effect was observed for
ionomycin in DU-145, which caused a much more pro-
nounced induction of the release of sEPCR in DU-145
compared with PrEC and PC-3 cells. In LNCaP cells, all
these pharmacological agents were ineffective at inducing
sEPCR release. Furthermore, treatment of cells with
MbCD as a cholesterol-depleting agent stimulated the
release of sEPCR (Figure 3A). Interestingly, the effect of
MbCD on sEPCR release was highest in normal PrEC,
whereas in malignant prostate cell lines the stimulatory
effect was distinctly less (Figure 3A).
The pro-inflammatory cytokines, including IL-1b,I L -
6, TNF-a,a n dI F N - g, had variable influences on EPCR
shedding in prostate cells (Figure 3B). In normal PrEC
as well as malignant DU-145 and PC-3 cells, IL-1b and
TNF-a significantly increased sEPCR release, with the
most pronounced effects observed in DU-145 cells; in
contrast, IFN-g and IL-6 were almost ineffective. In
LNCaP cells, IL-1b and TNF-a had insignificant effects
on sEPCR release (Figure 3B).
A panel of pharmacological inhibitors of MAP kinases
produced variable effects on IL-1b-a n dT N F - a-induced
shedding of EPCR in DU-145 and PC-3 prostate cancer
cells (Figure 4A). Distinct attenuation of sEPCR release
in DU-145 cells was observed after treatments with PD-
98059 as pharmacological inhibitor of MEK/ERK 1/2
activity, SB-203580 as inhibitor of p38 MAPK, and SP-
600125 as inhibitor of c-Jun N-terminal kinase (JNK)
MAPK. In PC-3 cells, PD-98059 was effective at abolish-
ing both the IL-1b-a n dt h eT N F - a-induced release of
sEPCR, whereas SP-600125 significantly attenuated
TNF-a-induced but not IL-1b-induced shedding of
EPCR.
To confirm the conclusion that in PC-3 cells the
MEK/ERK 1/2 pathway is down-regulated, levels of ERK
1/2 phosphorylation in DU-145 and PC-3 cells were
measured using a cell-based ELISA assay. Under normal
conditions ERK 1/2 was more higher phosphorylated in
DU-145 cells than in PC-3 cells (Figure 4B). Exposure
of DU-145 cells, but not of PC-3 cells, to IL-1b and
TNF-a led to a further increase of phosphorylated ERK
1/2 which was attenuated by treatment with PD-98059.
Therefore, these data suggest that the MEK/ERK 1/2
pathway in PC-3 cells is down-regulated.
Involvement of metalloproteases in shedding of EPCR in
prostate cells
The effects of 4-aminophenylmercuric acetate (APMA),
a generic organomercurial activator of metalloproteases,
and TAPI-0, a broad spectrum protease inhibitor, indi-
cated involvement of metalloproteases in shedding of
EPCR (Figure 5). More specifically, treatment of cells
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Figure 2 Invasiveness of prostate cancer cells (A) and its correlation with EPCR expression (B). (A) Data bars represent the relative
invasion activity of normal PrEC and malignant LNCaP (LN), DU-145 (DU), and PC-3 prostate cell lines measured in 3D cell invasion assay
(Oris™). Serum starved cells were seeded onto basement matrix extract coated plates. Following 48 hr incubation, cells were labeled with
Calcein AM and the fluorescence in the analytic zone was quantified using a plate reader, Victor3 1420 Multilabel Counter. Data are expressed as
changes relative to PrEC cell migration which was assigned a value of 1.0. Results are the means ± SDs of analyses in quadruplicates and are
representative of two independent experiments (B) Correlation of invasion activity and EPCR-specific immunostainings in PrEC and prostate
cancer cell lines. Correlation coefficient was calculated using SigmaPlot 11 (Systat software, Inc.).
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increase (by about 14- and 12-fold) of released sEPCR
levels in DU-145 and PC-3 cells than in untreated cells.
In LNCaP cells, treatment with APMA led also to a sig-
nificant, but less pronounced increase (by about 2.6-
fold) of sEPCR release. In PrEC the effect of APMA on
sEPCR release did not differ significantly compared to
untreated cells (Figure 5). Conversely, the release of
sEPCR was significantly attenuated by 30 μM TAPI-0 in
all analyzed cell lines (Figure 5).
In order to assess the functionality of EPCR expressed
in prostate cells, the activation of protein C in depen-
dence on APMA-induced EPCR shedding was studied.
In non-cancerous PrEC as well as in cancerous DU-145
and PC-3 cells nearly similar levels of aPC were
produced from exogenously added protein C (Figure 6).
In LNCaP cells, weak expression of EPCR correlated
with a small generation of aPC. After induction of
sEPCR release by APMA the levels of generated aPC
significantly decreased in PrEC, DU-145 and PC-3 cells.
There was no evident APMA-mediated effect on protein
C activation in LNCaP cells (Figure 6).
Discussion
The present study elucidates novel findings concerning
the expression and shedding of EPCR in normal epithe-
lial prostate cells (PrEC) and malignant LNCaP, DU-
145, and PC-3 prostate cell lines. In particular, our data
establishes that EPCR is up-regulated in DU-145 and
PC-3 cell lines compared to normal PrEC or less
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Figure 3 Stimulation of sEPCR release in normal PrEC and prostate cancer cell lines by pharmacological agents and pro-inflammatory
cytokines. Cells were incubated for 1 h either with 100 ng/ml PMA, 3 μM ionomycin, 0.8 mM H2O2, and 4 mM MbCD (A) or with pro-
inflammatory cytokines (IFN-g, IL-1b, IL-6, and TNF-a) at final concentrations of 25 ng/ml (B). Released sEPCR in cell culture medium was
determined using sEPCR ELISA technique. Results are the means ± SDs of analyses in triplicates and are representative of two similar
experiments. * p < 0.05 versus controls without cytokines.
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Page 4 of 10invasive LNCaP malignant cells and that the expression
of EPCR correlates with the invasiveness of the various
prostate cell lines. Similar up-regulation of EPCR was
previously described in different primary malignant cells
and cell lines derived from tumours generally considered
to be poorly responsive to chemotherapy, such as colon
carcinomas, renal cell carcinomas, and melanomas
[9,17]. Increasing evidence suggests that an up-regula-
tion of EPCR may contribute to tumor progression, but
the underlying mechanisms remain obscure [17,18].
Pro-carcinogenic effects of EPCR are suggested to be
linked with the stimulation of aPC generation and anti-
apoptotic signaling [19]. Given the function of aPC as
an anticoagulant, it was hypothesized that EPCR
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Figure 4 Effects of MAPK signaling inhibitors on cytokine-induced EPCR shedding (A) and activation of ERK 1/2 pathway (B) in DU-145
and PC-3 prostate cancer cell lines. (A) Cells were pre-incubated with 50 μM PD-98059, 10 μM SB-203580, or 20 μM SP-600125 as indicated for
30 min and thereafter exposed to cytokines at a final concentration of 25 ng/ml for additional 5 h. Results are the means ± SDs of analyses in
triplicates and are representative of three independent experiments. * p < 0.05 versus control without cytokines; # p < 0.05 versus cells exposed
to cytokines alone. (B) DU-145 and PC-3 prostate cancer cells were incubated with cytokines at a final concentration of 25 ng/ml and 50 μM PD-
98059 as indicated for 10 min. Signals of total and phosphorylated forms of ERK 1/2 (P-ERK 1/2) were determined using cell-based ELISA kit. OD,
optical density. Results are the means ± SDs of analyses in triplicates and are representative of two similar experiments. * p < 0.05 versus control
without cytokines and PD-98059; # p < 0.05 versus cells treated with cytokines, but not with PD-98059.
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Page 5 of 10expression by tumour cells provides a growth advantage
by maintaining a coagulation-free environment in vivo
[17]. Binding of aPC to corresponding receptors, EPCR
and PAR-1, leads also to a stimulation of cell motility,
invasion, and angiogenesis [13,20]. In addition, aPC may
affect cellular invasion either via direct activation of
matrix metalloproteases or by binding to plasminogen
activator inhibitor-1 leading to activation of extracellular
matrix proteases and thereby increasing cellular invasion
[21,22].
Despite of these pro-carcinogenic effects, an inhibitory
role of the aPC/EPCR pathway on tumor-endothelium
interactions has been described recently [15]. This anti-
metastatic effect of therapeutic doses of aPC is realized
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Figure 5 Effects of modulation of metalloprotease activities on sEPCR release in prostate cells. Bars show the effects of metalloprotease
inhibitor, 30 μM TAPI-0, and metalloprotease activator, 60 μM APMA, on shedding of EPCR in prostate cells. Released sEPCR was measured in
culture medium of cells treated with and without TAPI-0 and APMA as indicated using ELISA technique. Pr, prostate epithelial cells; LN, LNCaP
cells; DU, DU-145 cells; and PC, PC-3 cells, respectively. The release of sEPCR in control (without TAPI-0 and APMA treatment) was assigned as
100%. Results are the means ± SDs of analyses in triplicates and are representative of three independent experiments. * p < 0.05 versus control
without TAPI-0 or APMA.
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Figure 6 Effects of APMA as metalloproteinase activator on thrombin-dependent activation of protein C in prostate cells. Levels of aPC
were determined after a 2 hr-incubation period in prostate cells without or with 60 μM APMA exposure. Subsequently, cells were washed and
further incubated for 1 h in the presence of 4 μg/ml protein C and 0.12 NIH U thrombin/well. Aliquots of supernatants were transferred into 96-
well plates and assayed for aPC generation using chromogenic substrate S-2366. Results are the means ± SDs of analyses in triplicates and are
representative of two independent experiments. * p < 0.05 versus controls without APMA.
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tion. Further evidence suggests that endogenous aPC
limits cancer cell extravasation and cancer cell-induced
vascular leakage in a sphingosine-1-phosphate receptor-
1 dependent manner [16]. In view of these findings it is
of great interest to understand in detail the mechanisms
regulating the exposition of EPCR on the malignant cell
surface. First, previous studies demonstrated that levels
of EPCR exposed at endothelial cell surfaces are mark-
edly changed by its ectodomain cleavage and release in
soluble form (sEPCR) [23-25]. Second, released sEPCR
promotes an increased tendency for coagulation, prob-
ably through competition for aPC/PC [17,26]. In line
with these activities, increased levels of sEPCR may
interfere with the above-mentioned anti-metastatic
effects of aPC.
Similar to previous observations in HUVEC [25], the
shedding of EPCR in normal PrEC and malignant pros-
tate DU-145 and PC-3 cell lines is induced by PMA,
ionomycin, and H2O2.F u r t h e r m o r e ,M bCD as a disrup-
tor of lipid rafts increases the release of sEPCR in these
cells. The observation that the effect of MbCD on sEPCR
release is lower in DU-145 and PC-3 cells in comparison
to normal PrEC can be explained by elevated cholesterol
levels in cancer cells compared to non-cancerous cells,
increased amounts of lipid rafts and reduced sensitivity
to decreased cholesterol levels [27,28].
In addition to these pharmacological agents, pro-
inflammatory cytokines such IL-1b and TNF-a,b u tn o t
INF-g and IL-6 induce the release of sEPCR in PrEC,
DU-145, and PC-3 cells. These data agree with previous
observations in HUVEC [25]. However, in LNCaP cells
neither pharmacological agents nor IL-1b and TNF-a
led to increased release of sEPCR. Herein a further spe-
cific feature exists in this cell line that agrees with other
already described clear differences between LNCaP and
androgen-independent cell lines, DU-145 and PC-3, in
terms of their regulation of the phosphatidylinositol 3-
kinase (PI3K)/protein kinase B (PKB/Akt), Jak/STAT3,
JNK MAPK and other signaling pathways [29-31].
In order to further elucidate the mechanisms responsi-
ble for the IL-1b and TNF-a-mediated increase of
sEPCR release in invasive prostate cell lines we investi-
gated the involvement of MAPK pathways using selec-
tive inhibitors. Previously we described that in HUVEC
the cytokine-induced shedding of EPCR is mediated by
down-stream MAP kinases including ERK 1/2, JNK, and
p38 pathways [25]. Here, it is shown that the effects of
IL-1b and TNF-a on EPCR shedding in DU-145 cells
are also mediated by ERK 1/2, JNK, and p38 MAPK sig-
nalling cascades. In PC-3 cells, however, the MEK/ERK
1/2 pathway is down-regulated. This is supported
further by the observation that PD-98059 failed to
attenuate the cytokine-induced sEPCR release and that
IL-1b and TNF-a did not elevate the phosphorylated
MEK/ERK-1/2 fraction in these cells. This finding may
also explain the limited effects of IL-1b,T N F - a,a n d
ionomycin on sEPCR release in PC-3 compared to DU-
145 cells. Moreover, numerous cellular effects of hydro-
g e np e r o x i d ea r ek n o w nt ob em e d i a t e db ya b e r r a n t
activation of the MEK/ERK-1/2 pathway [32]. This may
explain the low efficiency of H2O2 as shedding inducer
in PC-3 in comparison to DU-145 cells (Figure 3A).
This study also shows that shedding of EPCR is dis-
proportionally induced by the metalloprotease activator,
APMA, in invasive DU-145 and PC-3 cells compared to
PrEC and less invasive LNCaP cells. This difference can
be explained by the well-known up-regulation of metal-
loproteases in DU-145 and PC-3 cells than in normal or
less invasive prostate cells [33]. The importance of
metalloproteases in EPCR shedding is shown also by the
complete inhibition of sEPCR release through the
broad-spectrum inhibitor of metalloproteases, TAPI-0,
in all analyzed cell lines.
To elucidate the functionality of EPCR in normal and
malignant prostate cells we addressed two questions: (i)
whether exogenous protein C is converted into aPC in
PrEC and malignant prostate cells and (ii) whether the
generation of aPC is modified by treatment of cells with
APMA. Our finding that generation of aPC in DU-145
and PC-3 cell lines is similar to PrEC and that it is sig-
nificantly diminished after APMA-mediated induction of
EPCR shedding suggests that the protein C pathway in
PrEC, DU-145, and PC-3 is functionally active and that
increased levels of EPCR at DU-145 and PC-3 cell sur-
faces may contribute to effective aPC production. In
LNCaP cells, the low protein C activation correlates
with down-regulated expression of EPCR.
Conclusions
This study brings to light new information concerning
expression and shedding of EPCR in normal and malig-
nant human prostate cell lines. The demonstrated up-
regulation of EPCR in invasive cancer cell lines may
provide a potential biological marker for prostate malig-
nancies. Cell surface levels of EPCR can effectively be
changed by activation or inhibition of cell signaling cas-
cades and metalloproteases involved in its shedding.
The present elucidation of mechanisms underlying the
regulation of expression and proteolytic cleavage of
EPCR suggests new potential avenues to interfere with
tumour growth and malignancy.
Materials and methods
Materials
Phorbol-12-myristate 13-acetate, PD-98059, SB-203580,
SP-600125, TAPI-0, ionomycin, thrombin, and recombi-
nant hirudin were from Calbiochem (Schwalbach,
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Page 7 of 10Germany). Human plasma-derived PC and aPC were
from Hematological Technologies Inc. (Cell Systems,
Biotechnologie Vertrieb GmbH, St. Katharinen,
Germany). Calcein AM, bovine serum albumin (BSA),
4-aminophenylmercuric acetate, and methyl-b-cyclodex-
trin were purchased from Sigma-Aldrich (Deisenhofen,
Germany). Recombinant human IL-1b,T N F - a,I F N - g,
and IL-6 were from Roche Diagnostics GmbH (Man-
nheim, Germany), chromogenic substrate S-2366 from
Haemochrom Diagnostica GmbH (Essen, Germany).
Calcein AM, PMA, PD-98059, SB-203580, SP-600125,
TAPI-0, ionomycin, and APMA were dissolved in
dimethyl sulfoxide (DMSO). The final concentrations of
DMSO were 0.3% or less, and controls using DMSO
alone were run in all cases. Other agents were used
as aqueous solutions. Monoclonal anti-EPCR antibody
produced in rat, RCR-252, and anti-rat IgG-FITC conju-
g a t e da n t i b o d yp r o d u c e di ng o a tw e r ef r o mS i g m a -
Aldrich (Deisenhofen, Germany).
Cell culture and incubation
Normal human prostate epithelial cells (PrEC; Cambrex
Bio Science, Walkersville, MD, USA) were maintained
up to a maximum of six passages in prostate epithelial
growth medium supplemented with bovine pituitary
extract, epidermal growth factor, insulin, transferrin,
hydrocortisone, retinoic acid, epinephrine, triiodothyro-
nine and gentamicin-amphotericin solution, according
to the manufacturer’s instruction. Every two to three
days the medium was changed and before reaching con-
fluence, cells were passaged using trypsin/EDTA.
Human prostate malignant cell lines (PC-3, DU-145,
and LNCaP cells) were purchased from German Collec-
tion of Microorganisms and Cell Cultures (Berlin,
Germany). They were cultured in standard cell culture
medium RPMI 1640 supplemented with 10% heat-
inactivated fetal calf serum (FCS), 2 mM L-glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin at
37°C in a humidified atmosphere of 5% CO2.
RNA Extraction and RT-PCR Analysis
RNA was isolated after lysis of cells in TRI Reagent
according to the manufacturer`s instructions. Isolated
RNA was converted to cDNA using the GeneAmp
RNA-PCR Kit (PerkinElmer LAS GmbH, Jügesheim,
Germany). A portion of the RT reaction products was
then amplified for identification of EPCR- and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH)-specific
mRNA as a reference gene using PCR. Early described
primers were used to amplify the coding sequences of
human EPCR: 5’-TGG CCT TTC CTC TGA CCA
TCC-3` (sense) and 5’-GGA GCT CCC ATT CAC AGC
CAC-3` (antisense) giving PCR products with a length
of 100 bp [34]. The further applied primer pair was
5`-CGG AGT CAA CGG ATT TGG TCG TAT TG-3`
and 5`-GCA GGA GGC ATT GCT GAT GAT CTT G-
3` for GAPDH amplifying products with 439 bp length.
Primer pairs were applied in a final concentration of
0.8 μM. The buffers and reagents used were from Gene-
Amp Kit (PerkinElmer LAS GmbH). After amplification,
the PCR products were subjected to agarose gel electro-
foresis and photographed using a G:BOX Chemi, GelVue
UV Transilluminator devise (SynGene, USA). Images
were analysed using GeneTools software from SynGene.
Flow cytometry
After incubation cells were scraped off the culture dishes,
washed in phosphate buffered saline (PBS), pH 7.4, and
resuspended at 1 × 10
6 cells/ml in FACS buffer (PBS sup-
plemented with 1% BSA and 0.1% sodium azide). Cells
were then incubated with anti-EPCR rat monoclonal
antibody RCR-252 added to a final concentration of 2.5
μg/ml for 30 min at 4°C. Subsequently, cells were washed
twice with FACS-buffer and incubated under light pro-
tected conditions for 30 min at 4°C with FITC-conju-
gated anti-rat secondary antibodies, which were added to
a final dilution of 1:100 of the commercially supplied
stock solution. Finally, cells were again washed twice,
fixed in 4% paraformaldehyde in PBS, and analyzed on
EPICS XL flow cytometer (Beckman Coulter GmbH, Kre-
feld, Germany). Isotype rat IgG was used instead of pri-
mary antibodies as controls for EPCR determination.
ELISA based quantitative determination of sEPCR
Amounts of sEPCR released by prostate cells were
determined using Asserachrom sEPCR ELISA kits (Diag-
nostica Stago, Asnieres, France) according to the manu-
facturer`s instructions. For this purpose, cells were
grown to confluence in 96-well microplate in complete
medium. After this, the medium was refreshed and cells
were further incubated with inducers or inhibitors of
EPCR shedding. At the end of incubations, medium was
removed, centrifuged at 800 g for 10 min to remove the
cell debris and used for analysis without further dilution
to determine sEPCR levels released by cells. Total cell
protein was determined using a Bicinchoninic Acid
assay kit (Sigma-Aldrich, Deisenhofen, Germany) with
bovine serum albumin as internal standard.
Determination of ERK 1/2 phosphorylation with cell-based
ELISA
Prostate cancer cells were cultured in 96-well micro-
plates for quantitative determination of ERK 1/2 phos-
phorylation. On the day of experiments, culture medium
was replaced by serum-free growth medium. After a 30-
minute pre-incubation period with or without 50 μM
PD-98059 as a selective inhibitor of the MEK/ERK path-
way, either 25 ng/ml IL-1b or 25 ng/ml TNF-a was
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bated for set periods of time. Levels of total ERK and
phosphorylated ERK (P-ERK) were quantified in fixed
cells using a RayBio Cell-based P-ERK 1/2 (Thr202/
Tyr204) ELISA kit (BioCat GmbH, Heidelberg, Ger-
many) according to the manufacturer’s instructions.
Prostate cancer cell 3D invasion assay
Cell invasion was measured in vitro using Oris™ Cell
Invasion & Detection Assay (AMS Biotechnology Ltd,
Abingdon OX14 4SE, UK) according to the manufac-
turer`s instructions. Briefly, after serum starvation for
18 hr cells (50,000 cells/well) were seeded on the Oris™
BME (Basement Membrane Extract) coated microplate
and allowed to adhere overnight. Stoppers were
removed and cells were overlaid with BME in the pre-
sence of 10% FBS. After a 48-hr incubation, cells were
stained with Calcein AM reagent. The detection mask
was applied to the bottom of the microplate and fluores-
cence from cells in the detection zone was quantified
using a Victor3 1420 Multilabel Counter reader (Perki-
nElmer LAS GmbH, Rodgau Jügesheim, Germany) at
excitation/emission wavelengths of 485/520 nm.
Protein C activation assay
Cells were cultured in 24-well plates, treated as indi-
cated and subsequently washed three times in buffer A
containing 50 mM Tris-HCI (pH 7.5), 2 mM CaCl2, 100
mM NaCl, and 0.1% BSA. Washed cells were incubated
for 2 h at 37°C in the presence of human protein C (4
μg/ml), thrombin (0.12 NIH U pro well), and buffer A
in a final volume of 200 μl/well. Thereafter, 150 μlo f
supernatants were transferred into 96-well plates and
assayed for the generation of aPC using 0.8 mM chro-
mogenic substrate S-2366. To prevent nonspecific clea-
vages of S-2366 by thrombin, hirudin (10 antithrombin
units pro well) was added to each probe. Extinction of
reaction product was measured at 405 nm on Victor3
1420 Multilabel Counter reader. Amounts of generated
aPC were calculated using aPC standards and normal-
ized to cell protein content.
Data analysis
Data were analyzed by one-way analysis of variance
coupled with Dunnett’s post hoc test to compare each
experimental group with a nominated control group
using SPSS 14.0 software. Differences were considered
significant at P < 0.05.
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